JP2021529750A5 - - Google Patents

Info

Publication number
JP2021529750A5
JP2021529750A5 JP2020572793A JP2020572793A JP2021529750A5 JP 2021529750 A5 JP2021529750 A5 JP 2021529750A5 JP 2020572793 A JP2020572793 A JP 2020572793A JP 2020572793 A JP2020572793 A JP 2020572793A JP 2021529750 A5 JP2021529750 A5 JP 2021529750A5
Authority
JP
Japan
Prior art keywords
peptide epitopes
peptide
cancer
epitopes
epitope
Prior art date
Application number
JP2020572793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529750A (ja
JPWO2020006242A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039521 external-priority patent/WO2020006242A1/en
Publication of JP2021529750A publication Critical patent/JP2021529750A/ja
Publication of JPWO2020006242A5 publication Critical patent/JPWO2020006242A5/ja
Publication of JP2021529750A5 publication Critical patent/JP2021529750A5/ja
Priority to JP2024155116A priority Critical patent/JP2025001671A/ja
Pending legal-status Critical Current

Links

JP2020572793A 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択 Pending JP2021529750A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155116A JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862690441P 2018-06-27 2018-06-27
US62/690,441 2018-06-27
US201862757045P 2018-11-07 2018-11-07
US62/757,045 2018-11-07
US201962814200P 2019-03-05 2019-03-05
US62/814,200 2019-03-05
US201962855311P 2019-05-31 2019-05-31
US62/855,311 2019-05-31
PCT/US2019/039521 WO2020006242A1 (en) 2018-06-27 2019-06-27 Personalized cancer vaccine epitope selection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155116A Division JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Publications (3)

Publication Number Publication Date
JP2021529750A JP2021529750A (ja) 2021-11-04
JPWO2020006242A5 JPWO2020006242A5 (https=) 2022-07-06
JP2021529750A5 true JP2021529750A5 (https=) 2022-07-06

Family

ID=68986808

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572793A Pending JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択
JP2024155116A Pending JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155116A Pending JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Country Status (10)

Country Link
US (1) US20210268086A1 (https=)
EP (1) EP3813848A4 (https=)
JP (2) JP2021529750A (https=)
KR (1) KR20210038886A (https=)
CN (1) CN113365639A (https=)
AU (1) AU2019293244B2 (https=)
CA (1) CA3104673A1 (https=)
MX (1) MX2021000193A (https=)
SG (1) SG11202012770RA (https=)
WO (1) WO2020006242A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
JP2024533501A (ja) 2021-09-13 2024-09-12 オンコディーエヌエー 患者の腫瘍の個別化された新生抗原を生成する方法
EP4148146A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate personalized neoantigens of a tumor of a patient
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US20250144043A1 (en) * 2022-02-11 2025-05-08 Washington University Methods of assessing cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
JP2026502789A (ja) * 2022-10-31 2026-01-27 グリットストーン バイオ インコーポレイテッド 組み合わせパネルのセルフリーdnaモニタリング
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211595T1 (hr) * 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014071219A1 (en) * 2012-11-01 2014-05-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
EP3576751A4 (en) * 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES

Similar Documents

Publication Publication Date Title
JP2021529750A5 (https=)
JPWO2020006242A5 (https=)
US11248264B2 (en) Individualized vaccines for cancer
US20230190898A1 (en) Individualized vaccines for cancer
CN107430132B (zh) 预测可用于疫苗接种的t细胞表位
WO2012159643A1 (en) Individualized vaccines for cancer
EP2714071B1 (en) Individualized vaccines for cancer
Sharif et al. In silico design of CT26 polytope and its surface display by ClearColi™-derived outer membrane vesicles as a cancer vaccine candidate against colon carcinoma
RU2021101603A (ru) Отбор эпитопов для персонализированной противораковой вакцины
HK40098119A (en) Individualized vaccines for cancer
HK40006796B (en) Individualized vaccines for cancer
HK40052764A (en) Individualized vaccines for cancer
HK1191241A (en) Individualized vaccines for cancer
HK1191241B (en) Individualized vaccines for cancer
HK40052764B (en) Individualized vaccines for cancer
NZ617217B2 (en) Individualized vaccines for cancer
HK40000563A (en) Individualized vaccines for cancer
HK40000563B (en) Individualized vaccines for cancer